Literature DB >> 6237901

Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.

J A Hoogkamp-Korstanje.   

Abstract

The antibacterial activity of ciprofloxacin was compared to those of norfloxacin, pefloxacin, pipemidic acid, nalidixic acid, nitrofurantoin, sulfamethoxazole, trimethoprim, cephradine and amoxycillin. Agar dilution tests were performed with 631 clinical isolates from urinary and respiratory tract infections. Ciprofloxacin was found to be the most active drug tested against all gram-negative organisms and streptococci, with the exception of Streptococcus faecalis and Streptococcus pneumoniae. MIC 90 values of ciprofloxacin were as follows: for Enterobacteriaceae, 0.03-0.23 mg/l, Pseudomonas aeruginosa, 0.37 mg/l, Haemophilus influenzae, less than 0.015 mg/l, Staphylococcus aureus, 0.75 mg/l, Streptococcus pneumoniae, 1.89 mg/l, and Streptococcus faecalis, 0.95 mg/l. The inhibitory quotients for urine, serum and bronchial secretion showed that ciprofloxacin had the broadest spectrum of all agents tested and covered and clinically significant bacteria.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6237901     DOI: 10.1007/bf01977489

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  10 in total

1.  Pharmacokinetics of sulfamethoxazole plus trimethoprim in man and their distribution in the rat.

Authors:  D E Schwartz; J Rieder
Journal:  Chemotherapy       Date:  1970       Impact factor: 2.544

2.  [Studies on the pharmacokinetics of pipemidic acid in renal insufficiency (author's transl)].

Authors:  P Brühl; T Köhler; G Gundlach; C Krasemann
Journal:  Arzneimittelforschung       Date:  1981

3.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].

Authors:  A Thabaut; J L Durosoir
Journal:  Pathol Biol (Paris)       Date:  1982-06

5.  The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.

Authors:  P D Ellner; H C Neu
Journal:  JAMA       Date:  1981-10-02       Impact factor: 56.272

6.  In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.

Authors:  J A Hoogkamp-Korstanje; C A Meijer
Journal:  Eur J Clin Microbiol       Date:  1982-06       Impact factor: 3.267

7.  Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.

Authors:  M Eandi; I Viano; F Di Nola; L Leone; E Genazzani
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

8.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents.

Authors:  B A Body; R A Fromtling; S Shadomy; H J Shadomy
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

  10 in total
  25 in total

1.  Effect of renal impairment on distribution of ofloxacin.

Authors:  A Sanchez Navarro; J Martinez Lanao; M M Sanchez Recio; A Domínguez-Gil Hurlé; J M Tabernero Romo; J C Gomez Sanchez; M M Terreiro Delgado
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

2.  Clinical evaluation of treatment with ciprofloxacin.

Authors:  R Finch; M Whitby; C Craddock; A Holliday; J Martin; R Pilkington
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.

Authors:  K Borner; G Höffken; H Lode; P Koeppe; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reinitz
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

4.  Intraphagocytic activity of ciprofloxacin and CI 934.

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

5.  In vitro activity of five quinoline derivatives against nosocomial isolates of Staphylococcus and Pseudomonas species.

Authors:  F D Daschner; H M Just
Journal:  Eur J Clin Microbiol       Date:  1985-02       Impact factor: 3.267

6.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

Review 7.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

8.  In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.

Authors:  G P Bongaerts; J A Hoogkamp-Korstanje
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Klin Wochenschr       Date:  1987-08-17

10.  Pharmacokinetics of pefloxacin in renal insufficiency.

Authors:  G Montay; C Jacquot; J Bariety; R Cunci
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.